From 15d588048e080ab4556377cc5728e7fd69e4b58f Mon Sep 17 00:00:00 2001
From: Navan Chauhan <navanchauhan@gmail.com>
Date: Tue, 24 Nov 2020 00:18:51 +0530
Subject: [PATCH] added for 25th

---
 archive-covid-19/24 November, 2020.html   | 256 ++++++++++++++++++++++
 archive-daily-dose/24 November, 2020.html | 139 ++++++++++++
 index.html                                |   4 +-
 3 files changed, 397 insertions(+), 2 deletions(-)
 create mode 100644 archive-covid-19/24 November, 2020.html
 create mode 100644 archive-daily-dose/24 November, 2020.html
diff --git a/archive-covid-19/24 November, 2020.html b/archive-covid-19/24 November, 2020.html
new file mode 100644
index 0000000..176f468
--- /dev/null
+++ b/archive-covid-19/24 November, 2020.html	
@@ -0,0 +1,256 @@
+<!DOCTYPE html>
+<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
+  <meta charset="utf-8"/>
+  <meta content="pandoc" name="generator"/>
+  <meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
+  <title>24 November, 2020</title>
+  <style>
+    code{white-space: pre-wrap;}
+    span.smallcaps{font-variant: small-caps;}
+    span.underline{text-decoration: underline;}
+    div.column{display: inline-block; vertical-align: top; width: 50%;}
+    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
+    ul.task-list{list-style: none;}
+    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
+  </style>
+  <!--[if lt IE 9]>
+    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
+  <![endif]-->
+<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
+<body>
+<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
+<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
+<ul>
+<li><a href="#from-preprints">From Preprints</a></li>
+<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
+<li><a href="#from-pubmed">From PubMed</a></li>
+<li><a href="#from-patent-search">From Patent Search</a></li>
+</ul>
+<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
+<ul>
+<li><strong>Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized placebo-controlled trial in 120 patients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint, NCT04331899). In both the 60 patients receiving Lambda and the 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively (HR 0.94; 95% CI 0.64 to 1.39). At enrollment; 41% of subjects were SARS-CoV-2 IgG seropositive; compared to placebo, lambda tended to delay shedding cessation in seronegatives (aHR 0.66, 95% CI 0.39-1.10) and to hasten shedding cessation in seropositives (aHR 1.58, 95% CI 0.88-2.86; p for interaction = 0.03). Liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1" target="_blank">Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial</a>
+</div></li>
+<li><strong>Predicting COVID19 Critical Care Beds - The London North-West University Healthcare Trust Experience</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Our trust has an urgent need to make short-term (3-4 days in advance) informed operational decisions which take into account best-practice treatment regimens and known clinical features of COVID19 inpatients. We believe that any model which is relied upon for operational decision making should have clinically identifiable parameters. Our model9s parameters take into account the conversion rates from acute wards into wards equipped with Non-Invasive Ventilation (NIV) and Mechanical Ventilation (MV), the typical time that these conversions take place and, the historical non-COVID usage of NIV and MV beds. We have observed that this clinical performance is mathematically identical to a series of linear delays on the time varying inpatient level. High frequency inpatient data, sampled ~4 hourly, has allowed our hospital trust to predict total critical care usage up to 4 days in advance without making any assumptions on upcoming inpatients. It is based entirely upon current bed occupancy levels and measured clinical pathways. Through back-testing over the recent 4 months, the bounds of this model include 93.8% of all 4 day inpatient sequences. The average next-day error is 0.8 (95% CI: 0.44, 1.15) and so the system tends to over-predict the next day critical care inpatients by approximately 1 bed. Potential extensions to the basic model include adjustments for seasonality, case mix, probabilistic marginalisation and known discharges.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235226v1" target="_blank">Predicting COVID19 Critical Care Beds - The London North-West University Healthcare Trust Experience</a>
+</div></li>
+<li><strong>Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Background. Antigen-detecting rapid diagnostic tests for SARS-CoV-2 offer new opportunities for the quick and laboratory-independent identification of infected individuals for control of the SARS-CoV-2 pandemic. Methods. We performed a prospective, single-center, point of care validation of two antigen-detecting rapid diagnostic tests (Ag-RDT) in comparison to RT-PCR on nasopharyngeal swabs. Findings. Between October 9th and 23rd, 2020, 1064 participants were enrolled. The PanbioTM Covid-19 Ag Rapid Test device (Abbott) was validated in 535 participants, with 106 positive Ag-RDT results out of 124 positive RT-PCR individuals, yielding a sensitivity of 85.5% (95% CI: 78.0-91.2). Specificity was 100.0% (95% CI: 99.1-100) in 411 RT-PCR negative individuals. The Standard Q Ag-RDT (SD Biosensor, Roche) was validated in 529 participants, with 170 positive Ag-RDT results out of 191 positive RT-PCR individuals, yielding a sensitivity of 89.0% (95%CI: 83.7-93.1). One false positive result was obtained in 338 RT-PCR negative individuals, yielding a specificity of 99.7% (95%CI: 98.4-100). For individuals presenting with fever 1-5 days post symptom onset, combined Ag-RDT sensitivity was above 95%. Interpretation. We provide an independent validation of two widely available commercial Ag-RDTs, both meeting WHO criteria of at least 80% sensitivity and at least 97% specificity. Although less sensitive than RT-PCR, these assays could be beneficial due to their rapid results, ease of use, and independence from existing laboratory structures. Testing criteria focusing on patients with typical symptoms in their early symptomatic period onset could further increase diagnostic value.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235341v1" target="_blank">Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers</a>
+</div></li>
+<li><strong>Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization (MR) analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and &gt;1 million controls. We found significant Mendelian randomization results for three proteins (ACE2: P=1.6x10^-6, IFNAR2: P=9.8x10^-11, and IL-10RB: P=1.9x10^-14) using cis-eQTL genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared eQTL signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.19.20234120v1" target="_blank">Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19</a>
+</div></li>
+<li><strong>Improved RT-PCR SARS-Cov2 results interpretation by indirect determination of cut-off cycle threshold value.</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+ABSTRACT Clinical laboratories of the developing world are overwhelmed with RT PCR SARS Cov2 testing demands. It is of paramount importance that each clinical laboratory use an appropriate cutoff value in the interpretation of SARS Cov2 realtime RT PCR results, which is specific to their laboratory performances as ISO 15189 recommendations stipulate. We applied an indirect statistical method to a large mixed data set of Ct values (ORF1ab and N) to estimate cut-off Ct value (~32 cycles).we conclude that the use of indirect statistical approaches to estimate cut-off value in the interpretation of SARS-Cov2 real-time RT PCR results may improve differential diagnosis of COVID 19 cases with low risk of infectivity, and may help to better estimates of the burden of COVID 19 disease.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235390v1" target="_blank">Improved RT-PCR SARS-Cov2 results interpretation by indirect determination of cut-off cycle threshold value.</a>
+</div></li>
+<li><strong>Antibody persistency and dynamic trend after SARS-CoV-2 infection over 8 months</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Abstract: An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 is critical for the development of diagnostic tests and vaccines. Our study aimed at the longitudinal analysis of antibody persistence and its dynamic trend over a period of eight months in a group of COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and 30th of March, 2020. The subjects were divided into two groups based on disease severity: mild and moderately-severe. The MAGLUMI 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post infection. The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.21.20236117v1" target="_blank">Antibody persistency and dynamic trend after SARS-CoV-2 infection over 8 months</a>
+</div></li>
+<li><strong>Antibody response patterns in COVID-19 patients with different levels of disease severity-Japan</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Background: We analyzed antibody response patterns according to level of disease severity in patients with novel coronavirus disease 2019 (COVID-19) in Japan. Methods: We analyzed 611 serum specimens from 231 patients with COVID-19 (mild, 170; severe, 31; critical, 30). IgM and IgG antibodies against nucleocapsid protein (N) and spike 1 protein (S1) were detected by enzyme-linked immunosorbent assays. Findings: The peaks of fitting curves for the OD values of IgM and IgG antibodies against N appeared simultaneously, while those against S1 were delayed compared with N. The OD values of IgM against N and IgG against both N and S1 were significantly higher in the severe and critical cases than in the mild cases at 11 days after symptom onset. The seroconversion rates of IgG were higher than those of IgM against both N and S1 during the clinical course based on the optimal cut-off values defined in this study. The seroconversion rates of IgG and IgM against N and S1 were higher in the severe and critical cases than in the mild cases. Conclusion: Our findings show that a stronger antibody response occurred in COVID-19 patients with greater disease severity and there were low seroconversion rates of antibodies against N and S1 in the mild cases. The antibody response patterns in our population suggest a second infection pattern, leading us to hypothesize that cross-reactivity occurs between SARS-CoV-2 and past infection with other human coronaviruses.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20231696v1" target="_blank">Antibody response patterns in COVID-19 patients with different levels of disease severity-Japan</a>
+</div></li>
+<li><strong>Comparing Machine Learning Algorithms for Predicting ICU Admission and Mortality in COVID-19</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+As predicting the trajectory of COVID-19 disease is challenging, machine learning models could assist physicians determine high-risk individuals. This study compares the performance of 18 machine learning algorithms for predicting ICU admission and mortality among COVID-19 patients. Using COVID-19 patient data from the Mass General Brigham (MGB) healthcare database, we developed and internally validated models using patients presenting to Emergency Department (ED) between March-April 2020 (n = 1144) and externally validated them using those individuals who encountered ED between May-August 2020 (n = 334). We show that ensemble-based models perform better than other model types at predicting both 5-day ICU admission and 28-day mortality from COVID-19. CRP, LDH, and procalcitonin levels were important for ICU admission models whereas eGFR &lt;60 ml/min/1.73m2, ventilator use, and potassium levels were the most important variables for predicting mortality. Implementing such models would help in clinical decision-making for future COVID-19 and other infectious disease outbreaks.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235598v1" target="_blank">Comparing Machine Learning Algorithms for Predicting ICU Admission and Mortality in COVID-19</a>
+</div></li>
+<li><strong>Duration of SARS-CoV-2 viral shedding in faeces as a parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding dynamics model</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Background: Wastewater-based epidemiology (WBE) is one of the most promising approaches to effectively monitor the spread of the novel coronavirus disease 2019 (COVID-19). The virus concentration in faeces and its temporal variations are essential information for WBE. While some clinical studies have reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentrations in faeces, the value varies amongst patients and changes over time. Aim: The present study aimed to examine how the temporal variations in the concentration of virus in faeces affect the monitoring of disease incidence. We re-analysed the experimental findings of clinical studies to estimate the duration of virus shedding and the faecal virus concentration. Method: Available experimental data as of 23 October, 2020 were collected and patient data reported in Germany were included for further analysis. The viral shedding kinetics was modelled, and the dynamic model was fitted to the collected experimental data by a Bayesian framework. Using samples of posterior distributions, the duration of viral shedding and the concentration of virus copies in faeces over time were computed. Results: We estimated the median concentration of SARS-CoV-2 in faeces as 2.6 (95% Credible Interval (CrI): 0.22-4.8) log copies per gram (g) of faeces over the shedding period, and our model implied that the duration of viral shedding was 23.2 days (95% CrI: 19.5-31.5), given the current standard quantification limit (Ct = 40). With simulated incidences, our results also indicated that a one-week delay between symptom onset and wastewater sampling increased the estimation of incidence by 13.5%. Conclusions: Our results demonstrated that the temporal variation in virus concentration in faeces affects microbial monitoring systems such as WBE. The present study also implied the need for adjusting the estimates of virus concentration in faeces by incorporating the kinetics of unobserved concentrations. The method used in this study is easily implemented in further simulations; therefore, the results of this study might contribute to enhancing disease surveillance and risk assessments that require quantities of virus to be excreted into the environment.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.22.20236323v1" target="_blank">Duration of SARS-CoV-2 viral shedding in faeces as a parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding dynamics model</a>
+</div></li>
+<li><strong>Commitment of medical students during the COVID-19-pandemic in Germany</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Introduction: Due to the spreading of COVID-19, one key challenge was to reduce potential staff shortages in the healthcare sector. Besides a reactivation of retired healthcare workers, medical students were considered to support this task. We herein analysed the commitment of medical students during the COVID-19-pandemic as well as their burdens and anxieties. Methods: Via an online survey, medical students in Germany were asked regarding these themes. The survey period took place during a two-week period in April and Mai 2020. 1241 questionnairs were included in the analysis. Results: 67.9% [65.3; 70.5] of the participants reported that they volunteered during the pandemic. Simultaneously, 88.9% [86.9; 90.5] of the participants stated to be against a compulsory recruitment in this context. Students who volunteered showed a significantly lower anxiety index than students, who did not volunteer. Concerns about transferring the virus to patients or relatives were significantly higher than concerns about the students own infection. Conclusion: The results of this survey study suggest that the majority of students are working voluntary during the pandemic. They declared mostly that they had adequate opportunities to protect themselves. Finally, their biggest fear was to infect other patients, relatives, or friends.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.21.20236067v1" target="_blank">Commitment of medical students during the COVID-19-pandemic in Germany</a>
+</div></li>
+<li><strong>Distribution of Incubation Period of COVID-19 in the Canadian Context: Modeling and Computational Study</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+We propose an original model based on a set of coupled delay differential equations with fourteen delays in order to accurately estimate the incubation period of COVID-19, employing publicly available data of confirmed corona cases. In this goal, we separate the total cases into fourteen groups for the corresponding fourteen incubation periods. The estimated mean incubation period we obtain is 6.74 days (95% Confidence Interval(CI): 6.35 to 7.13), and the 90th percentile is 11.64 days (95% CI: 11.22 to 12.17), corresponding to a good agreement with statistical supported studies. This model provides an almost zero-cost approach to estimate the incubation period.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235648v1" target="_blank">Distribution of Incubation Period of COVID-19 in the Canadian Context: Modeling and Computational Study</a>
+</div></li>
+<li><strong>Pay-as-you-go LPG supports sustainable clean cooking in Kenyan informal urban settlement, including during a period of COVID-19 lockdown</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Approximately 2.8 billion people rely on polluting cooking fuels (e.g. wood, kerosene), exposing them to health-damaging household air pollution. A key access barrier to clean cooking fuels (e.g. liquefied petroleum gas) is affordability. By enabling households to pay in small increments, pay-as-you-go (PAYG) liquefied petroleum gas (LPG) could help promote clean cooking, and support continued LPG use through periods of economic downturn. We investigate the ability of PAYG LPG to sustain access to clean cooking from January 2018- June 2020, including during COVID-19 lockdown (March-June 2020) in an informal settlement in Nairobi, Kenya. We utilize novel PAYG LPG smart meter data to document cooking/spending patterns from 426 PAYG LPG customers and semi-structured interviews among a subset of seven households. Objective cooking pattern comparisons are made to those cooking with full 6kg cylinder LPG and polluting fuel users from 23 households in peri-urban Eldoret in western Kenya, using stove monitoring data. Average PAYG LPG consumption was 0.97 kg/capita/month (11.6 kg/capita/year) prior to COVID-19 lockdown. Despite adverse economic impacts of the lockdown, 95% of households continued using PAYG LPG, and consumption increased to 1.22 kg/capita/month (March-June 2020). Daily cooking events using PAYG LPG increased by 60% (1.07 events/day (pre-lockdown) to 1.72 events/day (lockdown)). In contrast, among seven households purchasing full 6kg cylinder LPG in Eldoret, average days/month using LPG declined by 75% (17 to four days) during COVID-19 lockdown. Median PAYG LPG payment frequency doubled (from every 8 days to every 4 days) during lockdown, while average payment amount was nearly halved (336 Kenyan Shillings (KSh)/US$3.08 to 179 KSh/US$1.64). Interviewed customers reported numerous benefits of PAYG LPG beyond fuel affordability, including safety, time savings, cylinder delivery and user-friendliness. PAYG LPG helped sustain clean cooking during COVID-19 lockdown, possibly averting increases in polluting cooking fuel use and associated household air pollution exposures.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235978v1" target="_blank">Pay-as-you-go LPG supports sustainable clean cooking in Kenyan informal urban settlement, including during a period of COVID-19 lockdown</a>
+</div></li>
+<li><strong>Role of asymptomatic COVID-19 cases in viral transmission: Findings from a hierarchical community contact network model</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Background: As part of on-going efforts to contain the COVID-19 pandemic, understanding the role of asymptomatic patients in the transmission system is essential to infection control. However, optimal approach to risk assessment and management of asymptomatic cases remains unclear. Methods: This study involved a SEINRHD epidemic propagation model, constructed based on epidemiological characteristics of COVID-19 in China, accounting for the heterogeneity of social network. We assessed epidemic control measures for asymptomatic cases on three dimensions. Impact of asymptomatic cases on epidemic propagation was examined based on the effective reproduction number, abnormally high transmission events, and type and structure of transmission. Results: Management of asymptomatic cases can help flatten the infection curve. Tracking 75% of asymptomatic cases corresponds to an overall reduction in new cases by 34.3% (compared to tracking no asymptomatic cases). Regardless of population-wide measures, family transmission is higher than other types of transmission, accounting for an estimated 50% of all cases. Conclusions: Asymptomatic case tracking has significant effect on epidemic progression. When timely and strong measures are taken for symptomatic cases, the overall epidemic is not sensitive to the implementation time of the measures for asymptomatic cases.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.21.20236034v1" target="_blank">Role of asymptomatic COVID-19 cases in viral transmission: Findings from a hierarchical community contact network model</a>
+</div></li>
+<li><strong>Biostatistical Investigation of Correlation Between COVID-19 and Diabetes Mellitus</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+COVID-19 is a highly infectious disease. Studies suggest that its severity is amplified in patients diagnosed with Diabetes Mellitus. In this study, the correlation between the prevalence of COVID-19 and Diabetes was analyzed at the regional and global scale using data extracted from WHO and IDF Diabetes Atlas. For the regional investigation data was assorted into ten regions including Central Asia, Middle east and western Asia, Africa, North America and the Caribbean, South east Asia, East Asia, Europe, South and Central America, South Asia and Oceania. The results show a positive correlation coefficient of 0.47 in Middle east and western Asia. While at the global scale analysis all the selected countries were considered together and a correlation coefficient of 0.32 was observed. This number was increased to 0.69 when the top most affected countries by COVID-19 were considered for the analysis. In order to investigate the time dependent relationship of the two diseases, the data was analysed in five windows of 45 days each since the beginning of pandemic. The results show an increasing pattern of the correlation coefficient in the last three windows. Overall, based on this study by increasing the prevalence of Diabetes Mellitus, the prevalence of COVID-19 cases may also increase.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.21.20235853v1" target="_blank">Biostatistical Investigation of Correlation Between COVID-19 and Diabetes Mellitus</a>
+</div></li>
+<li><strong>The Impact of Late-Career Job Loss and Genotype on Body Mass Index</strong> -
+<div>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Unemployment shocks from the COVID-19 pandemic have reignited concerns over the long-term effects of job loss on population health. Past research has highlighted the corrosive effects of unemployment on health and health behaviors. This study examines whether the effects of job loss on changes in body mass index (BMI) are moderated by genetic predisposition using data from the U.S. Health and Retirement Study (HRS). To improve detection of gene-by-environment (G x E) interplay, we interacted layoffs from business closures (a plausibly exogenous environmental exposure) with whole-genome polygenic scores (PGSs) that capture genetic contributions to both the population mean (mPGS) and variance (vPGS) of BMI. Results show evidence of genetic moderation using a vPGS (as opposed to an mPGS) and indicate genome-wide summary measures of phenotypic plasticity may further our understanding of how environmental stimuli modify the distribution of complex traits in a population.
+</p>
+</div>
+<div class="article-link article-html-link">
+🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.20.20235895v1" target="_blank">The Impact of Late-Career Job Loss and Genotype on Body Mass Index</a>
+</div></li>
+</ul>
+<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</strong> - <b>Condition</b>:   COVID-19<br/><b>Intervention</b>:   Drug: Nafamostat Mesilate<br/><b>Sponsor</b>:   Chong Kun Dang Pharmaceutical<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: AZD7442;   Drug: Placebo<br/><b>Sponsors</b>:   AstraZeneca;   QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: AZD7442;   Drug: Placebo<br/><b>Sponsors</b>:   AstraZeneca;   QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Dietary Supplement: Rhea Health Tone®<br/><b>Sponsors</b>:   Universitas Padjadjaran;   PT. Rhea Pharmaceutical Sciences Indonesia;   Prodia Diacro Laboratories P.T.<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intravenous Infusion of CAP-1002 in Patients With COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: CAP-1002;   Biological: Placebo<br/><b>Sponsor</b>:   Capricor Inc.<br/><b>Recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Clarithromycin 500mg;   Drug: Azithromycin;   Drug: Placebo<br/><b>Sponsor</b>:   South Valley University<br/><b>Completed</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Dietary Supplement: Probiotics (2 strains 10x10^9 UFC);   Dietary Supplement: Placebo (potato starch and magnesium stearate)<br/><b>Sponsors</b>:   Centre de recherche du Centre hospitalier universitaire de Sherbrooke;   Lallemand Health Solutions<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fase I Clinical Trial on NK Cells for COVID-19</strong> - <b>Conditions</b>:   Covid19;   Sars-cov 2<br/><b>Intervention</b>:   Biological: Natural Killer Cells infusion<br/><b>Sponsor</b>:   Hospital de Clinicas de Porto Alegre<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) &amp; Two dose regimen;   Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) &amp; Three dose regimen;   Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) &amp; Two dose regimen;   Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) &amp; Three dose regimen;   Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) &amp; Two dose regimen;   Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) &amp; Three dose regimen;   Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) &amp; Two dose regimen;   Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) &amp; Three dose regimen;   Biological: Low-dose placebo (18-59 years) &amp; Two dose regimen;   Biological: Low-dose placebo (18-59 years) &amp; Three dose regimen;   Biological: High-dose placebo (18-59 years) &amp; Two dose regimen;   Biological: High-dose placebo (18-59 years) &amp; Three dose regimen;   Biological: Low-dose placebo (60-85 years) &amp; Two dose regimen;   Biological: Low-dose placebo (60-85 years) &amp; Three dose regimen;   Biological: High-dose placebo (60-85 years) &amp; Two dose regimen;   Biological: High-dose placebo (60-85 years) &amp; Three dose regimen<br/><b>Sponsors</b>:   Jiangsu Province Centers for Disease Control and Prevention;   West China Hospital<br/><b>Recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients</strong> - <b>Condition</b>:   Covid-19 Pneumonia<br/><b>Intervention</b>:   Biological: immune plasma<br/><b>Sponsor</b>:   Azienda USL Toscana Nord Ovest<br/><b>Recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hydrogen Therapy in Patients With Moderate Covid-19</strong> - <b>Condition</b>:   Covid-19<br/><b>Intervention</b>:   Drug: Mixture 3,6% H2 in N2 (96.4%)<br/><b>Sponsor</b>:   University Hospital, Grenoble<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Drug: Chloroquine<br/><b>Sponsor</b>:   Fundacion Clinica Valle del Lili<br/><b>Active, not recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Adaptive COVID-19 Treatment Trial 4 (ACTT-4)</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Baricitinib;   Drug: Dexamethasone;   Other: Placebo;   Drug: Remdesivir<br/><b>Sponsor</b>:   National Institute of Allergy and Infectious Diseases (NIAID)<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Dietary Supplement: Vitamin D3 (cholecalciferol);   Dietary Supplement: Zinc (zinc gluconate);   Dietary Supplement: Zinc (zinc gluconate) &amp; Vitamin D (cholecalciferol);   Other: Placebo<br/><b>Sponsors</b>:   Harvard School of Public Health;   Foundation for Medical Research;   University Health Network, Toronto<br/><b>Not yet recruiting</b></p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID)</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Other: Respiratory rehabilitation program (RR).;   Other: Respiratory tele-rehabilitation program (TRR).<br/><b>Sponsor</b>:   Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer<br/><b>Not yet recruiting</b></p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cordycepin: a bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against COVID-19</strong> - Spike protein and main proteases of SARS-CoV-2 have been identified as potential therapeutic targets and their inhibition may lead to the reticence of viral entry and replication in the host body. Despite several efforts; till now no specific drugs are available to treat SARS-CoV-2. Considering all these challenges, the main objective of the present study was to establish therapeutic potential of cordycepin against COVID-19 as a conventional therapeutic strategy. In the present study; molecular…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury</strong> - A screen by Kost-Alimova et al.¹ suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Molecular Interaction Analysis of Sulawesi Propolis Compounds with SARS-CoV-2 Main Protease as Preliminary Study for COVID-19 Drug Discovery</strong> - Coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health concern, as the World Health Organization declared this outbreak to be a global pandemic in March 2020. The need for an effective treatment is urgent because the development of an effective vaccine may take years given the complexity of the virus and its rapid mutation. One promising treatment target for COVID-19 is SARS-CoV-2 main protease. Thus,…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>To Have or Not to Have Sex? COVID-19 and Sexual Activity Among Chinese-Speaking Gay and Bisexual Men in Hong Kong</strong> - CONCLUSION: Sexual desire and COVID-19-related barriers serve as driving and inhibiting factors in explaining whether or not people have sex during the COVID-19 pandemic. Suen YT, Chan RCH, Wong EMY. To Have or Not to Have Sex? COVID-19 and Sexual Activity Among Chinese-Speaking Gay and Bisexual Men in Hong Kong. J Sex Med 2020;XX:XXX-XXX.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells</strong> - No abstract</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues</strong> - With the current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. The inhibition of viral entry and thus spread is a plausible therapeutic avenue. SARS-CoV-2 uses receptor-mediated entry into a human host via the angiotensin-converting enzyme 2 (ACE2), which is expressed in lung tissue as well as the oral and nasal mucosa,…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV</strong> - Among seven coronaviruses that infect humans, three (SARS-CoV, MERS-CoV, and the newly identified SARS-CoV-2) are associated with a severe, life-threatening respiratory infection and multiorgan failure. We previously proposed that the cationically modified chitosan, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC) is a potent inhibitor of HCoV-NL63. Next, we demonstrated the broad-spectrum antiviral activity of the compound, as it inhibited all low pathogenic human coronaviruses…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model</strong> - Previously, our group predicted commercially available Food and Drug Administration (FDA) approved drugs that can inhibit each step of the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI). Unfortunately, additional clinically significant treatment options since the approval of remdesivir are scarce. To overcome the current coronavirus disease 2019…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs</strong> - CONCLUSION: The DSPD-2, DSPD-6, and DSPD-5 could be developed as potential inhibitors of SARS-CoV-2. Moreover, we suggest that targeting molecules to bind effectively to the S1 subsite could potentially increase the binding of molecules to the SARS-CoV-2 Mpro.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia</strong> - No abstract</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial</strong> - OBJECTIVES: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The purpose of this study is to investigate the efficacy and safety of Zilucoplan in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19</strong> - Today, the world is suffering from the pandemic of a novel coronavirus disease (COVID-19), a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic is the third fatal coronavirus outbreak that has already occurred in the 21st century. Even six months after its emergence, hundreds of thousands of people are still being infected with SARS-CoV-2, and thousands of lives are lost every day across the world. No effective therapy has been approved to…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses</strong> - Essential oils and their chemical constituents have been reported with well documented antimicrobial effects against a range of bacterial, fungal and viral pathogens. By definition, essential oils are a complex mixture of volatile organic compounds which are synthesized naturally in different parts of the plant as part of plants secondary metabolism. The chemical composition of the essential oils is dominated by the presence of a range of compounds including phenolics, terpenoids, aldehydes,…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pharmacological therapies against COVID-19 : state of the art, between hopes and disappointments</strong> - The COVID-19 outbreak has raised numerous attempts of diverse pharmacological interventions to improve the prognosis of the infection, especially among hospitalized patients due to an acute respiratory distress syndrome (ARDS). Initially, these interventions used known medications capable to directly target SARS-CoV-2 by investigating several antiviral therapies already applied with some success in other viral infections. Among them remdesivir appears to be the most promising drug against…</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin</strong> - CONCLUSIONS: Overall, our findings demonstrate that AZ can exert broad-spectrum antiviral effects against IAV and SARS-CoV-2, and could be served as a potential clinical anti-SARS-CoV-2 drug in emergency as well as a promising lead compound for the development of next-generation anti-IAV drugs.</p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19</strong> -</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법</strong> - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten</strong> -</p>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.</p></li>
+</ul>
+<img alt="embedded image" id="EMI-D00000"/>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Methods for treating Arenaviridae and Coronaviridae virus infections</strong> - Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:</li>
+</ul>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.</p>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Atemschutz-Baukastensystem</strong> -
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Atemschutz-Baukastensystem, das aufweist:</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine auf zumindest Mund und Nase einer Person aufsetzbare Maske (1), die einen Eingang (11) und einen Ausgang (12) aufweist, und</li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mindestens einen Schlauch (3, 31, 32),</li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wobei sämtliche Komponenten des Atemschutz-Baukastensystems modular ausgebildet und über Steckverbindungen oder Schraubverbindungen (115, 125, 155, 165, 175, 215, 315, 75, 915) miteinander verbindbar sind, um der Maske (1) Luft über deren Eingang (11) zuzuführen und/oder ausgeatmete Luft vom Ausgang (12) der Maske (1) wegzuführen.</li>
+</ul>
+<img alt="embedded image" id="EMI-D00000"/>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zur Übergabe und Dekontamination von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen</strong> -
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.</p></li>
+</ul>
+<img alt="embedded image" id="EMI-D00000"/>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물</strong> - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .</p>
+<pre><code>    JPEG
+    112020094463686-pat00017.jpg
+    48
+    135</code></pre></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新型冠状病毒中和性抗体滴度检测ELISA试剂盒</strong> - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒，其中包括：包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低，操作简单，高灵敏度、高特异性、高准确度的特点，可用于新型冠状病毒中和抗体的批量、快速检测。</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -</p>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.</p></li>
+</ul>
+<img alt="embedded image" id="EMI-D00000"/>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.</p></li>
+</ul>
+<img alt="embedded image" id="EMI-D00000"/>
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
+
+
+<script>AOS.init();</script></body></html>
\ No newline at end of file
diff --git a/archive-daily-dose/24 November, 2020.html b/archive-daily-dose/24 November, 2020.html
new file mode 100644
index 0000000..6048e80
--- /dev/null
+++ b/archive-daily-dose/24 November, 2020.html	
@@ -0,0 +1,139 @@
+<!DOCTYPE html>
+<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
+  <meta charset="utf-8"/>
+  <meta content="pandoc" name="generator"/>
+  <meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
+  <title>24 November, 2020</title>
+  <style>
+    code{white-space: pre-wrap;}
+    span.smallcaps{font-variant: small-caps;}
+    span.underline{text-decoration: underline;}
+    div.column{display: inline-block; vertical-align: top; width: 50%;}
+    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
+    ul.task-list{list-style: none;}
+    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
+  </style>
+  <!--[if lt IE 9]>
+    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
+  <![endif]-->
+<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
+<body>
+<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
+<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
+<ul>
+<li><a href="#from-apple-subreddit">From Apple Subreddit</a></li>
+<li><a href="#from-hacker-news">From Hacker News</a></li>
+<li><a href="#from-new-yorker">From New Yorker</a></li>
+<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
+<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
+<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
+<li><a href="#from-ars-technica">From Ars Technica</a></li>
+<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
+</ul>
+<h1 data-aos="fade-right" id="from-apple-subreddit">From Apple Subreddit</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Size comparison of the iPhone 12 Pro Max to previous handheld devices from Apple</strong></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Apple Offering Up to $150 Gift Card With Select Products on Black Friday Through Cyber Monday</strong></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Waze Integration With CarPlay Dashboard in Beta Testing</strong></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How to avoid macOS reinstallation errors on M1 Macs</strong></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Some HomePod mini users report WiFi connectivity problems, with no permanent fix available - 9to5Mac</strong></li>
+</ul>
+<h1 data-aos="fade-right" id="from-hacker-news">From Hacker News</h1>
+<ul>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Walmart Exclusive Wi-Fi Router Contains Backdoor to Control Devices</strong> - <a href="https://news.ycombinator.com/item?id=25189673">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Another free CA as an alternative to Let’s Encrypt</strong> - <a href="https://news.ycombinator.com/item?id=25188614">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Nintendo Switch uses my open source code</strong> - <a href="https://news.ycombinator.com/item?id=25186890">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Misfit Tractors a Money Saver for Arkansas Farmer</strong> - <a href="https://news.ycombinator.com/item?id=25189287">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>DevTerm - An Open Source Portable Terminal for Every Dev</strong> - <a href="https://news.ycombinator.com/item?id=25185842">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>GNU Guix 1.2.0</strong> - <a href="https://news.ycombinator.com/item?id=25187576">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Solomon Islands set to ban Facebook in the name of ‘national unity’</strong> - <a href="https://news.ycombinator.com/item?id=25186763">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Changed-block tracking and differential backups in QEMU</strong> - <a href="https://news.ycombinator.com/item?id=25189078">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ad block and you don’t stop</strong> - <a href="https://news.ycombinator.com/item?id=25188516">Comments</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Flexport plans to hire 250 engineers in 2021</strong> - <a href="https://news.ycombinator.com/item?id=25188821">Comments</a></p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How Close Is Humanity to the Edge?</strong> - Toby Ord, a philosopher who studies our species’s “existential risk,” has been both frightened and encouraged by our response to the pandemic.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How the Biden Administration Can Free Americans from Student Debt</strong> - In the anthropologist David Graeber’s view, the balance sheet must periodically be wiped clean, to free us from debt as an economic burden and as an ideology that distorts our interactions.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>State and Local Republicans Standing Up to Trump Are Putting National G.O.P. Leaders to Shame</strong> - As the President continues his attempts to retain the reins of power, at least some Republican officials at the state and local level have asserted that the election was free, fair, and decisive.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>When “Creatives” Turn Destructive: Image-Makers and the Climate Crisis</strong> - If money is the oxygen on which the fire of global warming burns, then P.R. campaigns and snappy catchphrases are the kindling.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What the New Vatican Report Shows About the Church’s Failures in Addressing Sexual Abuse</strong> - The example of Theodore McCarrick demonstrates the Church’s inability to deal with abuse in frank, clear terms.</p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Graeme Smith optimistic of good crowds during Australia’s tour of South Africa</strong> - Says the Newlands will definitely host a match</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>TNCA’s Cricket Administrative Committee to deal with ‘conflict of interest’ issue</strong> - Senthilnathan’s tenure as the chairman of the senior State selection panel to end</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Orlando Open Challenger | Prajnesh loses in final</strong> - Prajnesh Gunneswaran lost to Brandon Nakashima 6-3, 6-4 in the final of the Orlando Open Challenger tennis tournament here on Sunday. However, it was</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>India’s tour of Australia | Siraj draws strength from Kohli</strong> - Skipper’s advice keeps India pacer afloat in time of tragedy</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>India’s tour of Australia | Gill excited at playing against Australia</strong> - The dashing batsman has not set any personal goals for the series</p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Next swearing-in will take place at the proper time not early morning: Devendra Fadnavis</strong> - The BJP leader’s statement comes a year after his ‘morning coup’ with Ajit Pawar stunned Maharashtra</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BJP begins preparations for panchayat elections</strong> - In a bid to establish political hold at the grassroot level in rural areas, the ruling BJP has commenced preparations for the forthcoming elections to</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>‘CM more keen on saving his chair than protecting farmers’</strong> - Karnataka Pradesh Congress Committee (KPCC) president D.K. Shivakumar came down on Chief Minister B.S. Yediyurappa alleging him of focusing on saving</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sri Sathya Sai Global Council to come up next year</strong> - 95th birth anniversary celebrations of Sathya Sai Baba end at Puttaparti</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>HC asks govt. to relook at measure formulated in lieu of midday meal</strong> - The High Court of Karnataka on Monday asked the State government to re-examine the compensatory measure formulated to distribute foodgrains to eligibl</p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
+<ul>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trial of ex-president Sarkozy a landmark for France</strong> - Nicolas Sarkozy has gone on trial accused of corruption linked to his 2007 campaign funding.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid: Boris Johnson to unveil post-English lockdown plans</strong> - Boris Johnson will unveil the latest Covid plans, including lifting a ban on outdoor grassroots sport.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19: Oxford University vaccine is highly effective</strong> - The vaccine is cheaper than other options and easier to distribute around the world.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19 pandemic: Merkel ‘worried’ about vaccines for poor countries</strong> - The German leader voices concern after top economic powers promise a fair distribution of vaccines.</p></li>
+<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ATP Finals 2020: Daniil Medvedev beats Dominic Thiem to take title</strong> - Daniil Medvedev fights back to beat US Open champion Dominic Thiem and win the biggest title of his career at the ATP Finals.</p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
+<ul>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AstraZeneca’s COVID-19 vaccine shows success: Here’s how it stacks up to others</strong> - AstraZeneca used two dosages: One 62% effective, the other 90%, for 70% average. - <a href="https://arstechnica.com/?p=1725065">link</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Comcast to enforce 1.2TB data cap in entire 39-state territory in early 2021</strong> - Data cap comes to 12 more US states over four years after everyone else got it. - <a href="https://arstechnica.com/?p=1725050">link</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Archaeologists find two more bodies among the ruins of Pompeii</strong> - Two more victims of the 79 CE eruption of Mount Vesuvius are accounted for. - <a href="https://arstechnica.com/?p=1724984">link</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ford’s electric Mustang Mach-E gets its official EPA range</strong> - The EPA says the extended-range Mustang Mach-E can go 300 miles on a charge. - <a href="https://arstechnica.com/?p=1725030">link</a></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How a Thanksgiving Day gag ruffled feathers in Mission Control</strong> - “I don’t remember ever being so nervous or upset about something as I was then.” - <a href="https://arstechnica.com/?p=1723027">link</a></p></li>
+</ul>
+<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
+<ul>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The adjective for metal is metallic, but not so for iron,</strong> - <!-- SC_OFF --></p>
+<div class="md">
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+which is ironic.
+</p>
+</div>
+<!-- SC_ON -->
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">  submitted by   <a href="https://www.reddit.com/user/bot_10"> /u/bot_10 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jzi22z/the_adjective_for_metal_is_metallic_but_not_so/">[link]</a></span>   <span><a href="https://www.reddit.com/r/Jokes/comments/jzi22z/the_adjective_for_metal_is_metallic_but_not_so/">[comments]</a></span></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trump has done in 4 years what 80% of presidents fail to do in 8 years</strong> - <!-- SC_OFF --></p>
+<div class="md">
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Lose an election.
+</p>
+</div>
+<!-- SC_ON -->
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">  submitted by   <a href="https://www.reddit.com/user/swordstoo"> /u/swordstoo </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jz8i4r/trump_has_done_in_4_years_what_80_of_presidents/">[link]</a></span>   <span><a href="https://www.reddit.com/r/Jokes/comments/jz8i4r/trump_has_done_in_4_years_what_80_of_presidents/">[comments]</a></span></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What do you call two Irish lesbians having sex?</strong> - <!-- SC_OFF --></p>
+<div class="md">
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Gaelic.
+</p>
+</div>
+<!-- SC_ON -->
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">  submitted by   <a href="https://www.reddit.com/user/CringeCoyote"> /u/CringeCoyote </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jzanf0/what_do_you_call_two_irish_lesbians_having_sex/">[link]</a></span>   <span><a href="https://www.reddit.com/r/Jokes/comments/jzanf0/what_do_you_call_two_irish_lesbians_having_sex/">[comments]</a></span></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Why do teenage girls walk in groups of 3, 5 and 7?</strong> - <!-- SC_OFF --></p>
+<div class="md">
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+Because they literally can’t even
+</p>
+</div>
+<!-- SC_ON -->
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">  submitted by   <a href="https://www.reddit.com/user/MyMomsHotNoCap"> /u/MyMomsHotNoCap </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jzhhd2/why_do_teenage_girls_walk_in_groups_of_3_5_and_7/">[link]</a></span>   <span><a href="https://www.reddit.com/r/Jokes/comments/jzhhd2/why_do_teenage_girls_walk_in_groups_of_3_5_and_7/">[comments]</a></span></p></li>
+<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The swordfish has no natural predators to fear from…</strong> - <!-- SC_OFF --></p>
+<div class="md">
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
+….except the penfish, which is supposed to be even mightier.
+</p>
+</div>
+<!-- SC_ON -->
+<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">  submitted by   <a href="https://www.reddit.com/user/VERBERD"> /u/VERBERD </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/jyz517/the_swordfish_has_no_natural_predators_to_fear/">[link]</a></span>   <span><a href="https://www.reddit.com/r/Jokes/comments/jyz517/the_swordfish_has_no_natural_predators_to_fear/">[comments]</a></span></p></li>
+</ul>
+
+
+<script>AOS.init();</script></body></html>
\ No newline at end of file
diff --git a/index.html b/index.html
index 30a92ad..0302b54 100644
--- a/index.html
+++ b/index.html
@@ -13,9 +13,9 @@ Archive | Daily Reports
 <li> <a href="#covid-19">Covid-19</a>
 </li></li></ul>
 <h2 id="daily-dose">Daily Dose</h2>
-<ul id="daily-dose-list"><li><a href="./archive-daily-dose/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-daily-dose/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-daily-dose/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-daily-dose/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-daily-dose/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-daily-dose/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-daily-dose/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-daily-dose/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-daily-dose/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-daily-dose/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-daily-dose/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-daily-dose/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-daily-dose/11 November, 2020.html">11 November, 2020</a></li>
+<ul id="daily-dose-list"><li><a href="./archive-daily-dose/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-daily-dose/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-daily-dose/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-daily-dose/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-daily-dose/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-daily-dose/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-daily-dose/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-daily-dose/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-daily-dose/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-daily-dose/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-daily-dose/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-daily-dose/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-daily-dose/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-daily-dose/11 November, 2020.html">11 November, 2020</a></li>
 </ul>
 <h2 id="covid-19">Covid-19</h2>
-<ul id="covid-19-list"><li><a href="./archive-covid-19/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-covid-19/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-covid-19/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-covid-19/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-covid-19/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-covid-19/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-covid-19/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-covid-19/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-covid-19/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-covid-19/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-covid-19/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-covid-19/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-covid-19/11 November, 2020.html">11 November, 2020</a></li>
+<ul id="covid-19-list"><li><a href="./archive-covid-19/24 November, 2020.html">24 November, 2020</a></li><li><a href="./archive-covid-19/23 November, 2020.html">23 November, 2020</a></li><li><a href="./archive-covid-19/22 November, 2020.html">22 November, 2020</a></li><li><a href="./archive-covid-19/21 November, 2020.html">21 November, 2020</a></li><li><a href="./archive-covid-19/20 November, 2020.html">20 November, 2020</a></li><li><a href="./archive-covid-19/19 November, 2020.html">19 November, 2020</a></li><li><a href="./archive-covid-19/18 November, 2020.html">18 November, 2020</a></li><li><a href="./archive-covid-19/17 November, 2020.html">17 November, 2020</a></li><li><a href="./archive-covid-19/16 November, 2020.html">16 November, 2020</a></li><li><a href="./archive-covid-19/15 November, 2020.html">15 November, 2020</a></li><li><a href="./archive-covid-19/14 November, 2020.html">14 November, 2020</a></li><li><a href="./archive-covid-19/13 November, 2020.html">13 November, 2020</a></li><li><a href="./archive-covid-19/12 November, 2020.html">12 November, 2020</a></li><li><a href="./archive-covid-19/11 November, 2020.html">11 November, 2020</a></li>
 </ul>
 </body></html>
\ No newline at end of file
